Answers are grounded in this paper and cite their sources.
BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is characterized by hepatic steatosis and can progress to steatohepatitis. Netrin-3, an axon guidance protein linked to metabolic homeostasis, has not been characterized in MAFLD. METHODS: MAFLD was induced in mice by high-fat diet. Netrin-3 and UNC5A expression was measured in serum and liver. Recombinant Netrin-3 was administered with or without Compound C. Hepatic AMPK/ACC phosphorylation, PPARα and target genes, lipid and glucose profiles, insulin, and liver injury were assessed. AML12 hepatocytes with fatty acid overload were treated with Netrin-3, Compound C, or AMPKα siRNA. RESULTS: Netrin-3 and UNC5A were downregulated in MAFLD mice. Netrin-3 treatment reduced body weight, adiposity, dyslipidemia, hyperglycemia, hyperinsulinemia, ALT/AST levels, and hepatic steatosis. It increased AMPK and ACC phosphorylation and restored PPARα, Fabp1, and CPT1α expression. Compound C reversed these protective effects in vivo. In AML12 cells, Netrin-3 activated AMPK/ACC signaling, and this effect was abolished by Compound C and AMPKα siRNA. CONCLUSIONS: Netrin-3 attenuates MAFLD progression by activating the hepatic AMPK-PPARα axis and promoting fatty acid oxidation, identifying Netrin-3 as a candidate therapeutic molecule for fatty liver disease.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: